drugset / Trial / NCT01762800

Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg

NCT01762800 ↗

Phase 4 Completed 407 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the control of COPD using a symptom and exacerbation risk based treatment strategy based on GOLD 2011. This study is conducted in Japanese subjects with COPD and assess whether the GOLD 2011 strategy is effective in medical practice in Japan.

Timeline

Start
2013-02
Primary completion
2015-09
Completion
2015-09

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

paper RESULTS: No data are available. PMID 24124358 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 50 ug —
Subject Salmeterol Other / unclassified 250 ug —
Subject Tiotropium Other / unclassified 18 ug —